The IRAK4 kinase inhibitor PF‐06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial
The IRAK4 kinase inhibitor PF‐06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation